AI Article Synopsis
- The study investigated the use of [Ga]pentixafor PET/CT for detecting nasopharyngeal carcinoma (NPC) and compared its effectiveness to the traditional [F]FDG PET/CT.
- A total of 25 NPC patients participated, showing equivalent detection rates for primary tumors (96% for both tracers) but differences in uptake values, with [Ga]pentixafor generally being lower.
- The findings suggest that [Ga]pentixafor PET/CT is a viable alternative for identifying NPC, particularly for primary and metastatic lesions, and could be useful in patient treatment planning.
Article Abstract
Purpose: This study aimed to explore the feasibility of [ Ga]pentixafor positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma (NPC).
Procedures: This prospective study included patients with NPC who underwent [ Ga]pentixafor PET/CT and 2-[F]fuoro-2-deoxy-D-glucose ([F]FDG) PET/CT within one week between November 2022 and March 2023. The [ Ga]pentixafor and [F]FDG uptakes in primary and metastatic lesions were measured and compared.
Results: Twenty-five participants (21 patients for initial stage and four patients for recurrence detection) were enrolled in our study. The participants underwent [F]FDG PET/CT and [ Ga]pentixafor PET/CT. [ Ga]pentixafor PET/CT had the same detection rate as [F]FDG for primary tumor (96% vs. 96%). The [ Ga]pentixafor maximum standard uptake value (SUV) and target-to-background ratio (TBR) of primary tumors were lower than those of [F]FDG (SUV: 8.13 ± 2.78 vs. 14.25 ± 6.45; P < 0.01; TBR: 5.17 ± 2.14 vs. 9.81 ± 5.30, P < 0.01). The difference between tumor volume of [ Ga]pentixafor (TV) and tumor volume of [F]FDG (TV) showed no significance (median: 16.01 vs. 9.56, P = 0.332). In the detection of suspected metastatic cervical lymph nodes (CLNs), [ Ga]pentixafor PET possessed a lower SUV than [F]FDG PET/CT (SUV: 6.86 ± 2.63 vs. 10.39 ± 5.28, P < 0.01), but there was no significant difference in the detection rate between [ Ga]pentixafor and [F]FDG PET/CT (96 vs. 98, P = 0.613).
Conclusions: [ Ga]pentixafor is a promising imaging tracer for detecting primary and metastatic NPC. [ Ga]pentixafor PET/CT is comparable to [F]FDG PET/CT in the detection rate of primary tumors and metastatic cervical lymph nodes in nasopharyngeal carcinoma, but [ Ga]pentixafor uptake was heterogeneous. [ Ga]pentixafor PET/CT may help select patients most likely to benefit from CXCR4-directed endoradiotherapy.
Clinical Trial Registration No: ChiCTR2200065902.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11307-024-01913-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Prospective Evaluation of Chemokine Receptor-4 (CXCR4) Overexpression in High-grade Glioma Using Ga-Pentixafor (Pars-Cixafor™) PET/CT Imaging.
Acad Radiol
December 2024
Division of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland (H.A., H.Z.); Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, Netherlands (H.Z.); Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark (H.Z.); University Research and Innovation Center, Óbuda University, Budapest, Hungary (H.Z.). Electronic address:
Background: While magnetic resonance imaging (MRI) remains the gold standard for morphological imaging, its ability to differentiate between tumor tissue and treatment-induced changes on the cellular level is insufficient. Notably, glioma cells, particularly glioblastoma multiforme (GBM), demonstrate overexpression of chemokine receptor-4 (CXCR4). This study aims to evaluate the feasibility of non-invasive Ga-Cixafor™ PET/CT as a tool to improve diagnostic accuracy in patients with high-grade glioma.
View Article and Find Full Text PDFDifferent extramedullary disease shown in chemokine receptor 4 targeted PET/CT with [ 68 Ga]Ga-pentixafor in patients with Waldenström macroglobulinemia and smoldering disease.
Nucl Med Commun
August 2024
Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, .
Introduction: It is important to distinguish Waldenström macroglobulinemia from smoldering Waldenström macroglobulinemia (sWM), because only patients with Waldenström macroglobulinemia require treatment, however the distinction can be clinically complex. The aim of this study is to investigate whether [ 68 Ga]Ga-pentixafor PET/CT shows different characteristics in sWM and Waldenström macroglobulinemia patients and therefore can help to differentiate Waldenström macroglobulinemia and sWM.
Results: Thirty-seven patients with newly diagnosed Waldenström macroglobulinemia and 11 sWM patients were analyzed [35 men and 13 women; 64.
[Tc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience.
Eur J Nucl Med Mol Imaging
November 2023
Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine and Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Rue du Bugnon 25A, Agora, CH-1011, Lausanne, Switzerland.
Purpose: The clinical success non-invasive imaging of CXCR4 expression using [ Ga]Ga-PentixaFor-PET warrants an expansion of the targeting concept towards conventional scintigraphy/SPECT with their lower cost and general availability. To this aim, we developed and comparatively evaluated a series of Tc-labeled cyclic pentapeptides based on the PentixaFor scaffold.
Methods: Six mas-conjugated CPCR4 analogs with different 4-aminobenzoic acid (Abz)-D-Ala-D-Arg-aa linkers (L1-L6) as well as the corresponding HYNIC- and N-analogs of L6-CPCR4 were synthesized via standard SPPS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!